Severe Atopic Dermatitis

Patients with moderate to severe atopic dermatitis showed promising results during and up to 20 weeks after treatment in a clinical trial evaluating rocatinlimab, according to a study.

The results of pooled safety data for Adbry showed positive effects in the prolonged treatment of moderate to severe atopic dermatitis, according to a study.

A 4 mg dose of baricitinib plus topical corticosteroids was associated with significant improvement over placebo in a phase 3 study of patients with moderate to severe atopic dermatitis, according to a study.

Cibinqo safely and effectively treated moderate to severe atopic dermatitis among patients regardless of any previous treatment with Dupixent, according to data published in the Journal of the American Academy of Dermatology.

Treatment with tralokinumab significantly improved symptoms among adolescents with moderate to severe atopic dermatitis, according to a study presented at the Western Society of Allergy, Asthma & Immunology Annual Scientific Meeting.

The FDA has accepted for priority review a supplemental biologics application for Dupixent that could allow treatment of moderate to severe atopic dermatitis in patients aged 6 months to 5 years, Regeneron announced in a press release.

The FDA approved cibinqo, an oral, once-daily JAK inhibitor, for the treatment of patients with moderate to severe atopic dermatitis, according to a press release.

Severe atopic dermatitis is associated with depression and internalizing behaviors in childhood and adolescence, according to a study.

Methotrexate and azathioprine yielded similar risk-benefit ratios as first-line therapy for children with severe atopic dermatitis, according to a study.

Induction therapy with abrocitinib was associated with low flare rates in patients with moderate to severe atopic dermatitis, according to a study.